Beta-Blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population
In conclusion, our study highlights the importance of BB dose escalation for survival and decreased hospitalization in patients with HF, regardless of race or HF type. It also suggests that benefits observed with high-dose BBs could be mediated, at least in part, by decreased cardiac fibrosis.
Source: Journal of Cardiovascular Pharmacology - Category: Cardiology Tags: Original Article Source Type: research
More News: Beta-Blockers | Cardiology | Cardiovascular | Drugs & Pharmacology | Electronic Health Records (EHR) | Heart | Heart Failure | Study | USA Health